To conclude, the concept that SPHK1 inhibition in combination with chemotherapeutic therapies might sensitize resistant cancer cells to currently inefficient regimens has emerged (Guillermet-Guibert et al. 2009). This evidence concerns the gene SPHK1 and cancer.